CervoMed Inc.CRVONASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank57
5Y CAGR-15.5%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

5Y CAGR
-15.5%/yr
Long-term compound
Percentile
P57
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
202514.37%
202440.61%
2023204.77%
2022-71.27%
202115.54%
202033.31%
2019-21.62%
2018-0.40%
2017-27.95%
2016240.76%